PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC (PROPHET)

  • STATUS
    Recruiting
  • End date
    May 10, 2030
  • participants needed
    83
  • sponsor
    Sun Yat-sen University
Send
Updated on 19 May 2025
See if I qualify

Summary

The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC. The main questions it aims to answer are:

  • Does ctDNA clearance indicate pathological complete response?
  • Are additional cycles of immunochemotherapy necessary for patients who have ctDNA clearance after initial cycles of treatment? Researchers will use ctDNA dynamics to guide the cycles of induction treatment to see if some patients can avoid excessive cycles of treatment.--UAT

Description

Advances in precision medicine have highlighted the potential of circulating tumor DNA (ctDNA) detection in NSCLC diagnosis, treatment efficacy monitoring, and prognosis evaluation. Induction immunotherapy combined with chemotherapy is now a standard treatment for patients with resectable NSCLC, but optimizing the number of immunochemotherapy cycles to enhance efficacy and reduce toxicity remains a critical clinical challenge. In this Phase II, proof-of-concept trial, around 83 patients with AJCC stage IIA-IIIB NSCLCs who are deemed resectable by an MDT team will participate to evaluate the potential role of dynamic ctDNA changes in guiding the cycle reduction of induction immunotherapy combined with chemotherapy while maintaining overall efficacy.

Eligible patients will receive 2 cycles (21-day intervals) of PD-1 inhibitor + platinum-based chemotherapy. Subsequent cycles (1-2 additional cycles) are determined by ctDNA status via tumour-agnostic strategies:

  1. For patients with ctDNA clearance: Randomized (1:1) to surgery or continued therapy.
  2. For patients with ctDNA persistence: Sequential 1-2 additional cycles. For all patients who are available to undergo surgery, the operation will be performed 4-6 weeks following the last cycle of treatment.

Details
Condition Non-small Cell Lung Cancer (NSCLC)
Age 18years - 75years
Clinical Study IdentifierNCT06977074
SponsorSun Yat-sen University
Last Modified on19 May 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histologically/cytologically confirmed, untreated stage IIA-IIIB NSCLC (IASLC 8th edition)
Deemed resectable by MDT
EGFR/ALK wild-type (non-squamous patients; squamous patients exempt)
ECOG PS 0-1
Adequate organ function (neutrophils ≥1.5×10⁹/L, platelets ≥100×10⁹/L, Hb >9 g/dL, Cr ≤1.5×ULN, AST/ALT ≤3×ULN)
Measurable lesions (RECIST 1.1)

Exclusion Criteria

Active autoimmune diseases (exceptions: vitiligo, type I diabetes, stable hypothyroidism)
Systemic corticosteroids (>10 mg prednisone equivalent/day) within 14 days
Grade 3-4 interstitial lung disease
Concurrent malignancies requiring treatment
Prior anti-PD-1/PD-L1/CTLA-4 therapy
Active HBV/HCV, HIV/AIDS, or pregnancy
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.56
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.57
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.58
Sign up59

Send a message24

Enter your contact details to connect with study team25

Investigator Avatar

Primary Contact26

First name*27
Last name*30
Email*33
Phone number*37
Preferred way of contact label
Race
Ethnicity
Other language43

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.